Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Summit Therapeutics ( (SMMT) ) has shared an announcement.
On June 12, 2025, Summit Therapeutics Inc. held its 2025 Annual Meeting of Stockholders where stockholders voted on the election of nine directors, the ratification of PricewaterhouseCoopers LLP as the independent public accounting firm for 2025, and an advisory vote on executive compensation. All proposals were approved in accordance with the Board’s recommendations, indicating strong shareholder support for the company’s governance and strategic direction.
The most recent analyst rating on (SMMT) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Summit Therapeutics stock, see the SMMT Stock Forecast page.
Spark’s Take on SMMT Stock
According to Spark, TipRanks’ AI Analyst, SMMT is a Neutral.
Summit Therapeutics’ stock score reflects significant financial challenges, including lack of revenue and ongoing losses, balanced by a strong equity position. Technical indicators show positive momentum, supporting short-term interest. Valuation remains weak due to negative earnings and no dividend. Positive clinical developments from the earnings call bolster the score, highlighting potential for future growth.
To see Spark’s full report on SMMT stock, click here.
More about Summit Therapeutics
Summit Therapeutics Inc. operates in the biotechnology industry, focusing on the development of novel therapies for serious unmet medical needs.
Average Trading Volume: 4,720,198
Technical Sentiment Signal: Buy
Current Market Cap: $14.82B
See more insights into SMMT stock on TipRanks’ Stock Analysis page.